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Brains from subjects who have Alzheimer’s disease (AD) express inducible nitric oxide 
synthase (iNOS). We tested the hypothesis that iNOS contributes to AD pathogenesis. 
Immunoreactive iNOS was detected in brains of mice with AD-like disease resulting from 
transgenic expression of mutant human 
 
 
 
-amyloid precursor protein (hAPP) and presenilin-1 
(hPS1). We bred hAPP-, hPS1-double transgenic mice to be iNOS
 
   
 
 or iNOS
 
   
 
, and 
compared them with a congenic WT strain. Deficiency of iNOS substantially protected the 
AD-like mice from premature mortality, cerebral plaque formation, increased 
 
 
 
-amyloid 
levels, protein tyrosine nitration, astrocytosis, and microgliosis. Thus, iNOS seems to be a 
major instigator of 
 
 
 
-amyloid deposition and disease progression. Inhibition of iNOS may be 
a therapeutic option in AD.
 
Alzheimer’s disease (AD) is a chronic degenera-
tive and inflammatory brain disorder that leads
to neuronal dysfunction and loss that are linked
to accumulation of fragments (A
 
 
 
[1–42/43]) of
 
 
 
-amyloid precursor protein (APP). A leading
possibility to explain how A
 
 
 
 accumulation leads
to neurotoxicity is that A
 
 
 
 triggers oxidative
and/or nitrosative injury. Fibrillogenic A
 
 
 
 elicits
the production of reactive nitrogen intermediates
(RNIs) and reactive oxygen intermediates from
microglia, astrocytes, neurons, and monocytes,
alone or synergistically with cytokines, in vitro
and when injected into the brain, in part by way
of induction of the inducible isoform of nitric
oxide synthase (iNOS; NOS2) (1–3). AD lesions
display biochemical and histochemical hallmarks
of oxidative and nitrosative injury, including
nitration of protein tyrosine residues (4–9),
which can report the vicinal production of per-
oxynitrite from NO and superoxide. However, a
functionally important source of AD-associated
oxidative or nitrosative brain injury has not
been identified that is a plausible target for
pharmacologic inhibition.
In 1996, iNOS was identified in AD lesions
(10). Collectively, that report and seven con-
firmatory studies identified iNOS immunore-
activity in neurons (7, 8, 10–12) and astrocytes
(7, 12–14) in brains of 75 patients who had
AD, but at far lower incidence, extent, and
intensity in brains from age-matched controls.
Although NOS1 (neuronal NOS) and NOS3
(endothelial NOS) are expressed constitutively
in normal brain, widespread expression of
iNOS in the central nervous system is patho-
logic, and has been observed in multiple sclerosis
(15), HIV-associated dementia (16), stroke (17),
amyotrophic lateral sclerosis (18), and Parkinson’s
disease (19). Because of its independence of
elevated intracellular Ca
 
2
 
 
 
 (20), iNOS catalyzes
a high-output pathway of NO production (21)
that is capable of causing neuronal damage
and death (16). Multiple mechanisms of NO-
dependent cytotoxicity have been identified.
For example, inhibition of the mitochondrial
electron transport chain by RNI (22) increases
mitochondrial production of superoxide anion,
and spurs formation of peroxynitrite, which
can exacerbate mitochondrial damage (23).
RNI can inhibit proteasomal degradation
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pathways (24), and perhaps contribute to the markedly de-
creased proteasome function that was documented in af-
fected regions of brains from patients who had AD (25). De-
creased proteasome function is likely to promote further
accumulation of A
 
 
 
 and advanced glycation products, which
leads to increased induction of iNOS (13). Based on these
observations, we hypothesized that inhibition of iNOS
might slow the progression of neuronal damage in individu-
als in whom levels of intracerebral A
 
 
 
 are elevated. To test
the foregoing hypothesis, we used a genetic approach by
breeding disrupted iNOS alleles into mice transgenic for
mutant human genes associated with AD.
 
RESULTS AND DISCUSSION
Construction of strains
 
First, we backcrossed the original iNOS
 
 
 
/
 
 
 
 C57BL/6
 
 
 
129
mice (26) to C57BL/6 for six generations. Descendants of
brother–sister matings of the latter mice were crossed with
the SJL strain, and their progeny were interbred to derive
iNOS
 
 
 
/
 
 
 
 C57BL/6
 
 
 
SJL mice. This step was based on evi-
dence that that modifier genes from the SJL background
were critical to avoid premature mortality in C57BL/6 mice
bearing a mutant (K670N, M671L) human APP (hAPP)
transgene (27). We bred the iNOS
 
 
 
/
 
 
 
 C57BL/6
 
 
 
SJL mice
with a strain called Tg2576, in which a hamster prion pro-
moter drives the K670N, M671L APP transgene in the
C57Bl/6
 
 
 
SJL background (28), and with transgenics in
which the Thy1 promoter drives human presenilin–1 (hPS1)
with the A246E mutation in the C57Bl/6
 
 
 
SJL background
(29). We interbred the progeny to establish three C57BL/
6
 
 
 
SJL sublines from littermates: (a) WT mice (iNOS
 
 
 
/
 
 
 
hAPP
 
0/0
 
 hPS1
 
0/0
 
); (b) mice with WT iNOS alleles and the
APP and PS1 transgenes, each of which was inherited from
only one parent so as to avoid overdose (iNOS
 
 
 
/
 
 
 
 hAPP
 
 
 
/0
 
hPS1
 
 
 
/0
 
); and (c) mice with disrupted iNOS alleles and the
APP and PS1 transgenes (iNOS
 
 
 
/
 
 
 
 hAPP
 
 
 
/0
 
 hPS1
 
 
 
/0
 
). Ge-
notypes were determined in all 3,691 mice that were re-
quired to generate and populate the experimental cohorts,
and were confirmed in all mice used in the study after the
last observation on each individual was recorded.
Anti-iNOS immunoblot detected the 130-kD iNOS
protein in the brains of the new subline of double-transgenic
mice with AD-like disease and WT iNOS alleles. The en-
zyme was not detected in brains of mice with AD-like dis-
ease whose iNOS alleles were disrupted, or in brains of mice
with WT iNOS alleles and no AD transgenes (Fig. 1). We
also detected immunohistologic reactivity for iNOS in the
brains of our double-transgenic mice and four other mouse
models of AD (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20051529/DC1). Our findings con-
firm and extend reports in which immunohistology, immu-
noblot, and enzyme assays identified iNOS in brains of
Tg2576 mice (28) and mice bearing the K670N, M671L hu-
man APP transgene driven by the Thy1 promoter in the
C57BL/6 background (30).
 
Impact of iNOS on AD transgene-dependent mortality
 
Comparison of the fate of the three congenic sublines al-
lowed us to test the hypothesis that iNOS exacerbates AD.
Mice with the AD-related transgenes and WT iNOS alleles
died much earlier than did the WT congenic subline. Defi-
ciency of iNOS exerted a marked protective effect against
AD-related mortality, and extended the time at which 75%
of the cohort remained alive from 143 d for iNOS
 
 
 
/
 
 
 
hAPP
 
 
 
/0
 
 hPS1
 
 
 
/0
 
 mice to 315 d for iNOS
 
 
 
/
 
 
 
 hAPP
 
 
 
/0
 
hPS1
 
 
 
/0
 
 mice—a 220% increase (P 
 
 
 
 0.0001, logrank test)
(Fig. 2 A). Even so, the iNOS
 
 
 
/
 
 
 
 hAPP
 
 
 
/0
 
 hPS1
 
 
 
/0
 
 mice
still died sooner than did congenic WT mice.
Male (Fig. 2 B) and female (Fig. 2 C) AD-transgenic
mice gained weight more slowly than did the WT mice
(P 
 
 
 
 0.0001, repeated measures ANOVA). However, iNOS
alleles had no effect on weight gain, and therefore, iNOS
was unlikely to hasten death by impairing feeding or drink-
ing. Moreover, time-lapse video camera recordings every 15
or 30 s over 24-h periods, covering 327 h of life of individu-
ally housed mice aged 3–5 mo, were scored by an observer
who was blind to mouse genotype. The video recordings re-
vealed no differences in feeding or other behavior between
AD-transgenic mice with and without intact iNOS alleles.
Both strains tended to sleep less (4.5 
 
 
 
 0.9 and 5.4 
 
 
 
 1.3
episodes per day totaling 519 
 
 
 
 50 and 581 
 
 
 
 115 min, re-
spectively) than did WT mice (8.8 
 
 
 
 1.3 episodes totaling
624 
 
 
 
 21 min; means 
 
 
 
 SD) and both rarely hung from the
cage lid, in contrast to WT mice. Necropsies of nine AD-
transgenic mice with or without intact iNOS alleles revealed
a distinct extracerebral pathology in each of four mice that
was judged to be incidental (see supplemental material).
Thus, the cause of premature mortality in the iNOS
 
 
 
/
 
 
 
hAPP
 
 
 
/0
 
 hPS1
 
 
 
/0
 
 strain was not established.
 
Impact of iNOS on AD transgene-dependent brain pathology
 
Cohorts of the three sublines were aged for 20, 40, and
60 wk. Brains from 10 mice per subline and time point
were examined for histopathology. No abnormalities were
observed in the WT controls. The double-transgenic
mice had age-dependent accumulation of plaques in all
areas examined: the cingulate, retrosplenial, and motor
cortices and the hippocampus. Deficiency of iNOS had
Figure 1. Expression of iNOS in brains of 60- to 64-wk-old mice 
with or without AD-related transgenes, as judged by immunoblot. 
Each lane is from a separate mouse of the genotypes indicated. Tubulin 
was immunostained as a loading control. 
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no effect on the accumulation of A
 
 
 
 during the first 40
wk of life, but markedly inhibited further accumulation
thereafter, so that plaque burden was reduced by 61% by
week 60 (Fig. 3, A–E). Immunoblot (Fig. 3, F and G) and
ELISA (Fig. 3 H) for A
 
 
 
 were consistent with the immu-
nohistologic findings; in immunoblot, A
 
 
 
 signal intensity
was reduced by 64% in the iNOS-deficient brains (P 
 
 
 
0.012, Student’s 
 
t
 
 test), whereas in ELISA, A
 
 
 
 reactivity
was diminished by 43% (P 
 
 
 
 0.04).
Figure 2. Amelioration of early mortality of AD-transgenic mice by 
disruption of iNOS alleles without an impact on weight gain. (top, 
Survival) Individually genotyped mice (iNOS /  hAPP0/0 hPS10/0, n   133; 
iNOS /  hAPP /0 hPS1 /0, n   140; iNOS /  hAPP /0 hPS1 /0, n   112) were 
inspected 5 d per week throughout their lifetime, and their mortality was plot-
ted as a function of age. Differences between any two curves were significant 
(P   0.0001; logrank test). (middle) Weight gain in males (iNOS /  hAPP0/0 
hPS10/0, n   43; iNOS /  hAPP /0 hPS1 /0, n   67; iNOS /  hAPP /0 hPS1 /0, 
n   48). (bottom) Weight gain in females (iNOS /  hAPP0/0 hPS10/0, n   41; 
iNOS /  hAPP /0 hPS1 /0, n   50; iNOS /  hAPP /0 hPS1 /0, n   50).
Figure 3. Amelioration of late-stage plaque formation and A  
deposition in AD-transgenic mice by disruption of iNOS alleles. 
(A) Representative sections from the neocortex and hippocampus of iNOS /  
hAPP /0 hPS1 /0 and iNOS /  hAPP /0 hPS1 /0 mice immunostained with 
A  (1–42) antibody. (B–E) Plaque burden (percentage of area occupied by 
A  [1–42]-immunoreactive plaques) and plaque numbers per unit area as a 
function of age in cortex (B and C) and hippocampus (D and E). Means   
SEM for 10 mice per strain per time point. Statistically significant differences 
are marked (*P   0.05; **P   0.01; ***P   0.003). No immunoreactivity was 
detected in mice lacking AD transgenes. Solid green line, iNOS /  hAPP /0 
hPS1 /0 mice. Dashed orange line, iNOS /  hAPP /0 hPS1 /0 mice. 
(F) Representative immunoblot for brain A  that was not extractable in 
physiologic saline or 0.5% Triton X-100, but was soluble in 6% SDS. 
Lane 1: iNOS /  hAPP /0 hPS1 /0 mice; lane 2: iNOS /  hAPP /0 hPS1 /0 
mice; lane 3: iNOS /  hAPP0/0 hPS10/0 mice. (G) Densitometry of four blots like 
that in F, each for different sets of mice, normalized to  -actin. The x axis sets 
to 1 the ratio of signal intensity for A  to that for  -actin in iNOS /  
hAPP /0 hPS1 /0 mice (solid bar marked “ / ”); the corresponding ratios for 
iNOS /  hAPP /0 hPS1 /0 mice (hatched bar marked “ / ”) are given as of a 
proportion of the ratio for the “ / ” mice in each of the same four blots 
(mean   SEM). (H) ELISA for A  in extracts prepared as in F. A  burden is 
indicated in  g/mg brain weight (mean   SEM, n   6) for the two strains 
with AD-related transgenes whose iNOS alleles are indicated as “ / ” 
(intact iNOS alleles, black bar) or “ / “ (disrupted iNOS alleles, gray bar).INDUCIBLE NO SYNTHASE IN MURINE ALZHEIMER’S DISEASE | Nathan et al. 1166
Deficiency of iNOS also reduced the extent of protein
tyrosine nitration in the brains of the AD-transgenic mice
markedly, as shown by immunostaining (Fig. 4 A) and slot-
blot (Fig. 4 B) using two different antibodies. Further, iNOS
deficiency afforded substantial protection against gliosis, as
judged by glial fibrillary acidic protein (GFAP) staining for
reactive astrocytes and CD40 staining for activated microglia
(Fig. 4, B–E; Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20051529/DC1). Finally, deficiency of
iNOS led to a reduction in accumulation of phosphorylated
tau protein around plaques as judged by immunostaining
(Fig. 4 G) and immunoblot (Fig. 4 H). By densitometric
analysis of immunoblots, the ratio of phospho-tau staining/
tubulin staining used as a loading control averaged 0.7   0.1
for WT mice, 1.2   0.6 for mice with AD-related transgenes
and disrupted iNOS alleles, and 2.7   0.0 for mice with AD-
related transgenes and intact iNOS alleles. Thus, iNOS defi-
ciency seemed to reduce tau phosphorylation by 56%.
In summary, iNOS, the catalyst of high-output pathway
of NO production (21), is expressed in human AD and in
many mouse models of AD. Mice with AD-like disease that
were unable to express iNOS genetically lived longer than
did their iNOS-expressing counterparts, formed fewer
plaques, had lower levels of brain A , suffered less protein
tyrosine nitration, accumulated less phosphorylated tau pro-
tein, and harbored fewer reactive astrocytes and microglia.
Figure 4. Amelioration of late-stage nitrosative/oxidative injury, 
astrogliosis, microgliosis, and phospho-tau accumulation in AD-
transgenic mice by disruption of iNOS alleles. (A) Nitrotyrosine 
immunoreactivity in the cingulate cortex of iNOS /  hAPP0/0 hPS10/0, 
iNOS /  hAPP /0 hPS1 /0, and iNOS /  hAPP /0 hPS1 /0 mice. (B) Nitroty-
rosine immunoblot. Brain extract proteins (150  g) were immobilized on a 
filter with a slot-blot apparatus and were immunoblotted with anti-nitro-
tyrosine mAb. (C–F) Reduction of GFAP staining indicative of astrocytosis 
(C and E) and of CD40 staining indicative of microgliosis (D and F) in the 
cortex (C and D) and hippocampus (E and F) of iNOS /  hAPP /0 hPS1 /0 
mice. Statistically significant differences are marked (***P   0.001; *P   0.05). 
(G) Reduction of phospho-tau immunoreactivity around plaques in 
iNOS /  hAPP /0 hPS1 /0 mice. Arrows highlight positive staining. 
(H) Anti–phospho-tau (p-tau) immunoblot with anti-tubulin as a loading 
control. Each lane is from a separate mouse of the genotypes indicated. 
See text for quantitative analysis.JEM VOL. 202, November 7, 2005 1167
BRIEF DEFINITIVE REPORT
It was shown that fibrillogenic A  promotes expression
of iNOS (1). However, the striking protective effect of
iNOS deficiency on plaque formation and accumulation of
A  deposits now suggests that iNOS is a major factor that
furthers the accumulation of A . Thus, iNOS and fibrillo-
genic A  each seem to promote the other’s accumulation.
Selective iNOS inhibitors that can enter the brain should be
tested for their ability to slow the progression of AD-like
disease in mice.
MATERIALS AND METHODS
Genotyping. Mice were bred and studied according to institutionally
approved protocols. The strains that were constructed for this study have
been deposited with the Mutant Mouse Regional Resource Centers for
distribution to other investigators (http://www.mmrrc.org/catalog/
StrainCatalogSearchForm.jsp). All 3,491 mice were genotyped by PCR
before adulthood. Those of the three genotypes that were included in this
study were genotyped again by PCR; 1 mouse failed to confirm and was
excluded from analysis. The specificity of the PCR reactions was con-
firmed by Southern blot in a subset of the mice. There were no instances
of discrepancy between PCR and Southern blot results. Each mouse was
genotyped by PCR using KlenTaq1 DNA polymerase and the following
primer pairs. For WT iNOS alleles, the common 5  primer (NOS-A) cor-
responds to bp 730–749 of the published sequence (31), and is located up-
stream of the deletion in the knockout mice: 5 -ATCAGCCTTTCTCT-
GTCTCC-3 . The 3  primer for WT iNOS (NOS-B) corresponds to bp
337–356 and with NOS-A will generate a 413-bp fragment: 5 -
GGCTTTCTGTCTGTTCTCTC-3 . For disrupted iNOS alleles, the 3 
primer for the mutant allele is homologous to sequences in the neomycin
gene and with NOS-A will generate a 268-bp fragment: 5 -GCCTGAA-
GAACGAGATCAGCAGCCTCTG-3 . For the hAPP transgene, a 300-
bp fragment is generated by the following primers (32): 5 -GTGGA-
TAACCCCTCCCCCAGCCTAGACCA-3  and 5 -CTGACCACTC-
GACCAGGTTCTGGGT-3 . For hPS1 transgene, an  300-bp fragment
is generated by the following primers: 5 -GTGAAGGAACCTTATTCT-
GTGGTG-3  and 5 -GTCCTTGGGGTCTTCTACCTTTCTC-3 .
Southern blot. Probes were amplified from genomic DNA using the fol-
lowing forward and reverse primers, respectively. For iNOS: 5 -GTC-
CAGGCTGGTACCTGACCTGACCTTAATGC-3 ; 5 -TTGGAGTG-
CTTGGCTGAATTCTGTTAT-3  (476 bp) (26). For the hAPP
transgene: 5 -GTGGATAACCCCTCCCCCAGCCTAGACCA-3  and
5 -CTGACCACTCGACCAGGTTCTGGGT-3 . ( 300 bp) (32). As a
control, a probe also was used for the endogenous prion protein: 5 -GTG-
GATAACCCCTCCCCCAGCCTAGACCA-3  and 5 -AAGCGGC-
CAAAGCCTGGAGGGTGGAACA-3  (  600 bp) (32). For the hPS1
transgene: 5 -GTGAAGGAACCTTATTCTGTGGTG-3  and 5 -GTC-
CTTGGGGTCTTCTACCTTTCTC-3  ( 300 bp). Probes were radiola-
beled with Prime-a-Gene (Promega). Phenol-chloroform–extracted ge-
nomic DNA (10  g) was restricted with KpnI for iNOS and with BamHI
or EcoRI for hAPP and hPS1.
Preparation of brains. For immunohistology, mice were anesthetized
deeply with pentobarbital and perfused intracardially with ice-cold 0.9% sa-
line followed by ice-cold 4% paraformaldehyde in 0.1 M sodium phosphate
buffer, pH 7.2 (PB). Brains were fixed  24 h in 10% neutral buffered for-
malin, washed in PB, and hemisected sagitally. One hemisphere was cryo-
protected in 30% glycerol, 30% ethylene glycol/0.02 M PB and stored at
 20 C for preparation of 35 micron frozen sections. The other hemisphere
was fixed in 10% neutral buffered formalin for  24 h, transferred to 70%
ethanol, and paraffin embedded by standard methods. For Western blots,
the perfusion omitted paraformaldehyde and the brains were placed directly
in the cryoprotectant solution.
To prepare brain extracts for anti-iNOS and anti-nitrotyrosine immu-
noblots, 150 ml 0.9% NaCl was used for transcardial perfusion without fix-
ative. Brain quarters were boiled for 10 min in 120  l sample buffer (200
mM Tris-HCl, pH 6.8, 4% SDS, 4%  -mercaptoethanol, and 20% glyc-
erol), followed by centrifugation at 14,000 g for 30 min, and supernatant
was stored at  80 C for immunoblot. Protein concentration was determined
by BioRad assay.
Antibodies. For immunohistology, rabbit anti-iNOS antiserum (anti-
holoiNOS) was raised against pure, native mouse iNOS (21), and subjected
to extensive documentation of monospecificity after ultracentrifugation. These
tests included, as a positive control, reactivity with cells in sections of foot-
pads from WT mice infected with Leishmania major (gift from R. Almeida,
(Federal University of Bahia, Bahia, Brazil) and livers from WT mice in-
jected with Propionobacterium acnes followed 6 d later by bacterial lipopolysac-
charide. As negative controls, we used livers from untreated WT mice and
livers from P. acnes– and LPS-treated iNOS knock-out mice. The antiserum
was positive with the positive controls, and negative with the negative con-
trols. The positive samples were negative using nonspecific rabbit IgG in
place of anti-iNOS or omitting primary antibody. Moreover, preimmune
rabbit serum gave no reaction with sections of brains from AD-transgenic
mice expressing iNOS. For further specificity controls, antibody to mouse
NOS1 (Santa Cruz K-20) was used to document reaction with NOS1 in
cerebellum of WT mice under the same conditions where the anti-iNOS
antiserum was negative with cerebellum. Antibody to mouse NOS3 (Santa
Cruz N-20) was used to document reaction with NOS3 in heart of WT
mice under the same conditions where the anti-iNOS antiserum was nega-
tive with heart. Finally, all results with immunohistochemistry were con-
firmed by immunoblot. Thus, anti-iNOS antiserum was monospecific for
iNOS in mouse, and did not react with mouse NOS1, mouse NOS3, or any
other detectable moiety in inflamed organs of iNOS-knock out mice. This
anti-iNOS antiserum was furnished to Upstate Biotechnology. Equivalent
results were obtained using the original antiserum and samples that we subse-
quently purchased from Upstate Biotechnology. We have reported similar
documentation of specificity for anti-iNOS mAbs 1E8B8 and 5BE36 (Re-
search & Diagnostic Antibodies) (33). For Western blot, we used rabbit anti-
iNOS amino terminal domain (Upstate Biotechnology). A  was stained
with an affinity-purified rabbit antibody specific to the COOH terminus of
the A (1–42) peptide (5  g/ml; cat. no. AB5078P; Chemicon). The fol-
lowing antibodies also were used: rabbit anti-GFAP (1:1,000; DakoCytoma-
tion), rat anti–mouse CD40 (1:100; Serotec), rabbit antinitrotyrosine (1:50;
Upstate Biotechnology), and rabbit polyclonal antibody against tau (phospho
T205; 1:100; Abcam Inc.). Antinitrotyrosine slot-blots used mAb 1A6
(0.5  g/ml) from Upstate Biotechnology.
Immunohistology. Specimens were provided by M. Sporn (Dartmouth
College, Hanover, NH); K. Hsiao (University of Minnesota, Minneapolis,
MN); J. Clemens (E. Lilly, Inc., Indianapolis, IN); P. Davies and L. Van
Der Ploeg (Merck, Inc., Rahway, NJ); K. Duff and Y. Masugi (New York
University, New York, NY); and S. Fu and J. Merrill (Aventis, Inc.,
Bridgewater, NJ). Staining for iNOS was performed on paraffin-embedded
sections as follows. For sections shown in Fig. S1, A–D, brains in cryopro-
tectant solution (30% ethanol [EtOH], 30% ethylene glycol, 0.02 M sodium
phosphate buffer, pH 7.2) were washed in sodium phosphate buffer and put
on a Tissue-Tek V.I.P. automated tissue processor with the following cy-
cles: 70% EtOH 45 min, 95% EtOH 45 min, 95% EtOH 45 min, 100%
EtOH 45 min, 100% EtOH 45 min, xylene 45 min, xylene 60 min, xylene
60 min, paraffin 60 min, paraffin 60 min, paraffin 120 min (total processing
time 10.5 h). Those shown in Fig. S1, E–F were processed for paraffin mi-
crotomy using standard vacuum paraffin infiltration. Sections (5  m) were
deparaffinized and blocked for endogenous biotin using the Avidin/Biotin
blocking kit (Biocare). Antigen retrieval was performed in Borg solution
(Biocare) in a pressure cooker for 5 min. Sections were stained with biotin-
ylated mAbs, using the MM Biotinylation Strep/HRT kit (Biocare), or rab-
bit polyclonal iNOS II (see above), using the Ultratek Strep/HRPINDUCIBLE NO SYNTHASE IN MURINE ALZHEIMER’S DISEASE | Nathan et al. 1168
(ScyTek). Stains were developed using Carassian DAB (Biocare) and
counterstained with Mayer’s hematoxylin.
Sections for A  (1–42) immunohistology were pretreated with 90% for-
mic acid for 5 min at room temperature before immunostaining. A modified
avidin-biotin peroxidase technique was used. In brief, sections were treated
with 3% H2O2 to block endogenous peroxidase. Sections were incubated se-
quentially in 1% BSA/0.2% Triton, primary antibody, appropriate biotinyl-
ated secondary antibody, and avidin-biotin peroxidase complex (Vector Lab-
oratories). The immunoreaction was visualized using 3,3 -diaminobenzidine
tetrahydrochloride dihydrate (DAB) with nickel intensification (Vector Lab-
oratories) as the chromogen. The sections were mounted onto gelatin-
coated slides, dehydrated, cleared in xylene, and coverslipped.
A  deposits were visualized and quantitated using a Nikon Eclipse
E600 microscope with a video camera attached to a computer. The A 
(1–42)-immunostained sections were viewed with a 10  objective, and digi-
tal images were captured using the Stereo Investigator 4.35 software pro-
gram (Microbrightfield). Images of brain areas (0.75 mm2) were saved as
tagged image format files. The regions analyzed included the retrosplenial/
motor cortex and CA1/dentate region of the hippocampus. The retrosple-
nial/motor cortex was analyzed in five sections (350  m apart) per mouse be-
ginning at the level of bregma  1.06. The CA1/dentate region was analyzed
in five sections (350  m apart) per mouse beginning at the level of bregma
 1.34. Quantitative analysis was performed using the NIH Image 1.63 soft-
ware. The threshold was set at 50. The data were exported to Microsoft Excel
for calculating the amyloid burden and mean number of plaques/0.75 mm2.
Amyloid burden was calculated as the percentage of area occupied by the A 
deposits in each region. The same procedure was used for quantifying micro-
gliosis. The percentage of CD40-immunolabeled area in each region was de-
termined. For quantitation of astrocytes, the optical fractionator was used to
estimate the number of GFAP-immunoreactive cells within the areas used for
quantification of A  plaque burden and number.
Immunoblots and ELISA. Brain extracts (150  g/mouse for iNOS blot;
50  g/mouse for nitrotyrosine blot) were fractionated by SDS-PAGE, trans-
ferred onto nitrocellulose membranes, and blotted with antibodies against
iNOS (see above) or phospho-T205 of tau (1:1,000, ab4841, Abcam Inc.).
Blots were developed with horseradish peroxidase–conjugated second anti-
body, visualized by enhanced chemiluminescence with a substrate kit (Pierce
Chemical Co.), and exposed to Kodak BioMax Mr film. Relative loading
among samples was assessed by reblotting the same membrane with anti–
 -tubulin (1  g/ml, ICN Biomedicals). For detecting nitrotyrosine proteins,
brain extracts (150  g/mouse) were mixed with 150  l Tris-glycine buffer
(25 mM Tris-OH, 190 mM glycine, pH 8.3 plus 20% MeOH), and loaded
onto a nitrocellulose membrane using a Hoefer PR648 slot blot. The filter
was blotted with anti-nitrotyrosine mAb and visualized as described before.
For A  immunoblots, unfixed brains were stored in cryoprotectant at
 20 C. The anterior third of the right hemisphere (50–70 mg) was lysed by
sonication (Branson Sonifier 250, 80% duty cycle, output 6) and sequentially
extracted in 10 volumes each of 10 mM phosphate buffered saline (138 mM
NaCl), pH 7.0 (PBS), followed by 0.5% Triton X-100 in PBS, and then 6%
SDS in water. All solutions contained a protease cocktail (Roche, Complete
Protease Inhibitor, 1 tablet/50 ml). Centrifugations were in a Beckman
TA15-1.5 rotor at 15,000 rpm (25,200 g) for 270 min, at 4 C. The final 6%
SDS extract was used for A  analysis. Protein concentration was determined
by a detergent-compatible Lowry technique (Biorad, DC Protein Assay). 10
 g of protein was subjected to 10–20% Tris-Tricine SDS-PAGE and transfer
to polyvinylidene fluoride membranes. Membranes were boiled in PBS for 5
min to expose epitopes, and then immunoblotted with 6E10, a mouse IgG1
mAb raised against human A  residues 1–17 (1:1,000; Signet Laboratories).
Bands were visualized by enhanced chemiluminescence. Image intensity was
quantified with Scion Image 4.02 software, and normalized to  -actin
immunostaining on the same blots.
A  ELISAs were performed on the same homogenates that were used for
A  Western blotting with a colorimetric kit (Biosource International), using
mAb 6E10 as above. Measurements were normalized to brain weight.
Video camera recordings. Mice were housed individually in cages
whose water bottles were replaced with gel packs located under the food
bin for improved visibility from above. The mice were kept in the standard
dark/light cycle, except that a very faint light for the dark cycle was sup-
plied by way of reflection from a 10-W shielded bulb pointed at the wall.
Recordings were made with an iSight camera (Apple Computer Inc.) con-
nected to a G4 PowerMacintosh (Apple Computer Inc.). The sensitivity of
the camera was increased  10-fold during the dark cycle. In the first period
of recordings, images were taken at 30-s intervals. Subsequently, the fre-
quency was increased to 15-s intervals. Images were collected by way of
EvoCam 3.5 software (Evological Inc., www.evological.com). Recordings
were analyzed by one observer, who was blind to the strain of the mice.
The observer looked for seizures (none was detected); logged periods of
sleep; and characterized motor activity, such as ambulation and hanging
from the cage lid. Sleep was defined as an interval of 8 min or longer during
which the mouse did not relocate its center of mass and was not engaged in
feeding. An interval of sleep was counted as one episode of sleep if it in-
cluded no more than one excursion lasting  1 min that was preceded and
followed by at least 8 min of immobility.
Online supplemental material. Fig. S1 provides immunohistologic evi-
dence for expression of iNOS in brains of mice with or without AD-related
transgenes. Fig. S2 illustrates CD40 staining in the cortex. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/
jem.20051529/DC1.
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